

CITATION REPORT

List of articles citing

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

DOI: 10.1053/gast.1997.v112.pm9024300
Gastroenterology, 1997, 112, 463-72.

Source: <https://exaly.com/paper-pdf/28239256/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1202	Treatment of acute and chronic hepatitis C. 1997 , 1, 615-30		12
1201	The natural history of chronic hepatitis C virus infection. 1997 , 1, 587-602		42
1200	Hepatitis C infection in transplantation. 1997 , 1, 663-90		22
1199	Clinical manifestations of hepatitis C. 1997 , 1, 569-85		22
1198	Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). 1997 , 27, 201-5		158
1197	Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. 1997 , 3, 628-37		257
1196	Molecular epidemiology of hepatitis C in Australia. 1998 , 13, 914-20		28
1195	Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. 1998 , 27, 1394-402		430
1194	Determinants of outcome of compensated hepatitis C virus-related cirrhosis. 1998 , 27, 1435-40		289
1193	Hepatitis C: somber views of natural history and optimistic views of interferon treatment?. 1998 , 27, 1443-4		23
1192	Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. 1998 , 27, 1717-22		274
1191	Clinical outcome of hepatitis C as a function of mode of transmission. 1998 , 28, 562-7		96
1190	Prognosis of chronic hepatitis C: results of a large, prospective cohort study. 1998 , 28, 1687-95		466
1189	Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. 1998 , 83, 901-9		112
1188	The natural course of chronic hepatitis C: implications for clinical practice. 1998 , 5 Suppl 1, 9-12		31
1187	Review article: interferon and hepatitis C--factors predicting therapeutic outcome. 1998 , 12, 509-18		16
1186	Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection. 1998 , 20, 388-97		6

1185	Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone. 1998 , 29, 369-74	14
1184	Alcohol, HCV infection, and liver cirrhosis: is the cup half full or half empty?. 1998 , 28, 728-30	5
1183	LIVER TRANSPLANTATION FOR ALCOHOLIC LIVER DISEASE. 1998 , 2, 839-850	4
1182	Clinician's guide to hepatitis C. 1998 , 73, 355-60; quiz 361	13
1181	Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. 1998 , 93, 2452-6	87
1180	Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. 1998 , 93, 2148-53	16
1179	Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. 1998 , 171, 433-5	83
1178	The clinical picture of acute and chronic hepatitis C. 1998 , 62, 102-18	7
1177	Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers. 1998 , 18, 75-80	18
1176	3. Chronic viral hepatitis. 1998 , 168, 619-626	6
1175	Hepatitis C: natural history, diagnosis, and management. 1999 , 56, 961-73; quiz 974-5	20
1174	Hepatitis Viruses. 187-233	
1173	Analytic Reviews : The Indications for and Timing of Liver Transplantation: Schluger LK, Klion FM The indications for and timing of liver transplantation J Intensive Care Med 1999,14 109-117. 1999 , 14, 109-117	
1172	Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection?. 1999 , 45, 475-6	6
1171	Indications for referral and assessment in adult liver transplantation: a clinical guideline. 1999 , 45, vi1-vi22	35
1170	A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. 1999 , 94, 1605-12	25
1169	Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. 1999 , 340, 1228-33	749
1168	Patient selection and listing policies for liver transplantation. 1999 , 14 Suppl, S42-7	14

1167	Natural history of chronic hepatitis B and C. 1999 , 14 Suppl, S1-5	40
1166	Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group. 1999 , 14, 1100-7	45
1165	The hepatic flaviviridae: summary. 1999 , 6 Suppl 1, 1-5	1
1164	Histological progression during short-term follow-up of patients with chronic hepatitis C virus infection. 1999 , 6, 445-52	11
1163	Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study. 1999 , 29, 300-7	21
1162	Severity of liver disease in hepatitis C infection contracted through injecting drug use. 1999 , 29, 776-81	8
1161	Research questions concerning hepatitis C virus: report from a workshop at the Harvard Center for Cancer Prevention. 1999 , 10, 485-7	1
1160	Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. 1999 , 44, 624-30	109
1159	Incomplete response of interferon treatment has an important role for the prevention of hepatocellular carcinoma. 1999 , 34, 655-6	
1158	The Indications for and Timing of Liver Transplantation. 1999 , 14, 109-117	1
1157	The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. 1999 , 29, 1311-6	217
1156	Modeling the hepatitis C virus epidemic in France. 1999 , 29, 1596-601	157
1155	Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. 1999 , 29, 1870-5	175
1154	Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. 1999 , 30, 271-6	53
1153	Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. 1999 , 30, 1318-24	147
1152	Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. 1999 , 85, 1943-1950	49
1151	Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. 1999 , 85, 2132-2137	177
1150	Factors contributing to the evolution and outcome of cirrhosis in hepatitis C. 1999 , 3, 741-55, viii	4

1149	Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. 1999 , 94, 1619-26	34
1148	Hepatitis C virus infection and lung transplantation: a survey of practices. 1999 , 18, 456-9	28
1147	Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. 1999 , 30, 653-9	210
1146	Hepatitis C: the clinical spectrum of the disease. 1999 , 31 Suppl 1, 9-16	181
1145	Natural history of hepatitis C. 1999 , 31 Suppl 1, 17-24	287
1144	Clinical significance of hepatitis C virus genotypes. 1999 , 31 Suppl 1, 65-70	81
1143	Hepatitis C and alcohol. 1999 , 31 Suppl 1, 113-8	55
1142	New treatment strategies in non-responder patients with chronic hepatitis C. 1999 , 31 Suppl 1, 184-8	16
1141	Treatment of patients with chronic hepatitis C and cirrhosis. 1999 , 31 Suppl 1, 197-200	7
1140	HEPATOCELLULAR CARCINOMA. 1999 , 3, 327-348	4
1139	Treatment of hepatitis C: a decision that needs careful consideration. 1999 , 107, 180-1	1
1138	Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. 2000 , 132, 517-24	554
1137	Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. 2000 , 133, 665-75	105
1136	5 Natural history of hepatitis C. 2000 , 2, 85-105	
1135	II Therapy of chronic hepatitis C. 2000 , 2, 203-239	3
1134	12 Hepatitis C and cirrhosis. 2000 , 241-263	2
1133	13 Hepatitis C and hepatocellular carcinoma. 2000 , 2, 265-275	2
1132	14 Hepatitis C and liver transplantation. 2000 , 2, 277-294	

1131	Antiviral therapy for chronic hepatitis B and C. Which patients are likely to benefit from which agents?. 2000 , 107, 135-8, 141-4	1
1130	Hepatitis C: a challenge for the generalist. 2000 , 35, 97-8, 101-4, 107-8 passim	2
1129	Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. 2000 , 135, 1456-9	106
1128	Estimating future hepatitis C morbidity, mortality, and costs in the United States. 2000 , 90, 1562-9	433
1127	A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. 2000 , 7, 249-56	51
1126	The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. 2000 , 88, 58-65	21
1125	Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. 2000 , 60, 126-132	16
1124	Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. 2000 , 89, 53-59	93
1123	Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. 2000 , 31, 54-8	192
1122	Which patients with hepatitis C develop liver complications?. 2000 , 31, 513-20	129
1121	"Silent killer" or benign disease? The dilemma of hepatitis C virus outcomes. 2000 , 31, 536-7	13
1120	Liver transplantation. American Association for the Study of Liver Diseases. 2000 , 6, 122-35	83
1119	A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. 2000 , 40, 1182-91	26
1118	Economic analysis of recombinant interferon β in the treatment of chronic hepatitis B and C. 2000 , 1, 29-34	
1117	Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. 2000 , 7, 196-202	107
1116	Treatment of chronic hepatitis C virus infection in patients with cirrhosis. 2000 , 7, 327-34	17
1115	Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. 2000 , 15 Suppl, D84-90	96
1114	Biochemical markers of hepatic fibrogenesis: single measurements are not reliable enough to replace liver biopsy. 2000 , 15, 819-21	13

1113	Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. 2000 , 15, 945-51	172
1112	Asian perspectives on viral hepatitis: hepatitis C virus infection. 2000 , 15 Suppl, G90-3	17
1111	Pretreatment viral load and response to interferon therapy for liver cirrhosis caused by hepatitis C virus: a multicenter controlled study. 2000 , 16, 124-138	
1110	Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. 2000 , 2, 166-85	26
1109	Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery. 2000 , 2, 1757-63	29
1108	Advances in the treatment of hepatitis C: combination antiviral therapy with interferon alfa-2b and ribavirin. 2000 , 12, 364-73	4
1107	Therapeutic options for HCV--management of the infected individual. 2000 , 14, 255-64	5
1106	Liver transplantation for hepatitis C virus related cirrhosis. 2000 , 14, 307-25	3
1105	Natural history of hepatitis C: its impact on clinical management. 2000 , 31, 1014-8	211
1104	Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. 2000 , 31, 997-1004	372
1103	Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. 2000 , 32, 852-8	432
1102	Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. 2000 , 32, 91-6	265
1101	[Etiology of hepatocellular carcinoma. The problem of the primary disease]. 2000 , 41, 185-90	2
1100	Cellular immune response in HCV infection. 2000 , 35, 881-9	4
1099	Hepatitis C Infection: Its Sequelaie and Outcomes [State-of-the-Art Workshop, September 24 to 25, 1998. 2000 , 14, 49B-59B	
1098	Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver. 2000 , 14 Suppl B, 5B-20B	28
1097	Hepatitis C. 2000 , 14 Suppl B, 67B-76B	14
1096	Hepatitis C: medical information update. Canadian Liver Foundation. National Hepatitis C Education Program. 2000 , 91 Suppl 1, S4-9	2

1095 Interferon Therapy in Liver Cirrhosis Type C. **2000**, 16, 81-88

1094 Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. **2000**, 30 Suppl 1, S77-84 214

1093 Hepatitis C. **2000**, 15 Suppl 8, 2-11 3

1092 Hepatitis B and C in the liver transplant recipient. **2000**, 20, 465-80 13

1091 Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. **2000**, 20, 17-35 562

1090 Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. **2000**, 160, 3365-73 79

1089 10 Worldwide prevalence and prevention of hepatitis c. **2000**, 185-IV 21

1088 Interferon therapy reduces the risk for hepatocellular carcinoma. **2000**, 47, 610-1 7

1087 Effects of interferon therapy on inhibition of hepatocellular carcinoma development in patients with chronic hepatitis C. **2000**, 30, 213-4 1

1086 Quality of life measurement in gastrointestinal and liver disorders. **2000**, 47, 444-54 140

1085 Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection. **2000**, 34, 487-94 26

1084 L'histoire naturelle de l'infection par le virus de l'hépatite c. **2000**, 30, S8-S13 1

1083 Hyperdynamic circulation in portal hypertension: a comparative model of arterio-venous fistula. **2000**, 55, 77-87 10

1082 Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. **2000**, 47, 131-6 273

1081 Predictors of liver-related complications in patients with chronic hepatitis C. **2000**, 32, 588-91 5

1080 Viral hepatitis in the liver transplant recipient. **2000**, 14, 761-84 24

1079 Liver transplantation at the millennium. Past, present, and future. **2000**, 4, 241-55 16

1078 Liver transplantation. Selection, listing criteria, and preoperative management. **2000**, 4, 513-32 9

1077	Hepatitis C. 2000 , 14, 633-67		15
1076	The current status of liver transplantation for primary hepatic malignancy. 2000 , 4, 591-605		21
1075	Liver transplantation. 2000 , 6, 122-135		3
1074	Hepatology in the new millennium. Advances in viral hepatitis, hepatic disorders, and liver transplantation. 2000 , 84, 1085-105		4
1073	Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. 2000 , 33, 651-658		23
1072	HCV-related fibrosis progression following liver transplantation: increase in recent years. 2000 , 32, 673-84		642
1071	Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. 2000 , 33, 423-9		19
1070	Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. 2000 , 33, 456-62		40
1069	Pathogenesis, diagnosis and management of hepatitis C. 2000 , 32, 98-112		119
1068	Liver transplantation: current status and novel approaches to liver replacement. <i>Gastroenterology</i> , 2001 , 120, 749-62	13.3	182
1067	Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. 2001 , 34, 593-602		305
1066	Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. 2001 , 35, 265-71		43
1065	Hepatitis C and liver transplantation. 2001 , 35, 666-78		231
1064	Cost-effectiveness of Interferon Alfa-2b With and Without Ribavirin as Therapy for Chronic Hepatitis C in Sweden. 2001 , 36, 870-876		29
1063	Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. 2001 , 111, 614-21		63
1062	Chronic hepatitis C: grading, staging, and searching for reliable predictors of outcome. 2001 , 32, 899-903		13
1061	A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. 2001 , 37, 1352-8		21
1060	Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention. 2001 , 47, 593-609		1

1059	Hepatitis C virus and liver transplantation. 2001 , 5, 1073-90	21
1058	Screening for cancer in viral hepatitis. 2001 , 5, 109-22	40
1057	The natural history of hepatitis C virus infection. 2001 , 5, 969-77	25
1056	Is pegylated interferon plus ribavirin set to become the standard therapy for patients with hepatitis C?. 2001 , 17, 5-8	
1055	Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. 2001 , 15, 225-38	33
1054	Management Guidelines for the HCV and HIV Co-Infected Adult: Recommendations of a Multidisciplinary Expert Panel. 2001 , 12, 8A-21A	
1053	Liver transplantation: evolving patient selection criteria. 2001 , 15, 729-38	21
1052	Prevention of hepatocellular carcinoma in chronic liver disease: molecular markers and clinical implications. 2001 , 19, 338-44	3
1051	A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. 2001 , 13, 483-8	33
1050	Liver transplantation for chronic hepatitis C: long-term results, role of antiviral therapy, and outcome of retransplantation. 2001 , 6, 114-119	5
1049	Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. 2001 , 32, 240-4	77
1048	Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. 2001 , 72, 861-8	84
1047	Therapeutic advances in the management of hepatitis B and hepatitis C. 2001 , 14, 593-601	8
1046	Chronic hepatitis C. Implications for health-related quality of life. 2001 , 24, 169-75; quiz 176-7	16
1045	Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. 2001 , 33, 20-6	52
1044	Models predicting the natural history of cirrhosis and need for liver transplantation. 2001 , 6, 107-113	3
1043	Concise review of the management of hepatitis C. 2001 , 27, 275-83	
1042	Hepatitis C and hepatocellular carcinoma. 2001 , 2, 473-83	26

1041	Hepatocellular cancer in liver transplantation. 2001 , 8, 427-34	13
1040	Hepatitis C virus infection in HIV-infected patients. 2001 , 3, 469-476	28
1039	Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. 2001 , 15, 689-98	100
1038	Hepatitis C in clinical practice. 2001 , 249, 111-20	13
1037	Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. 2001 , 8, 206-16	42
1036	Estrogen receptor levels and lipid peroxidation in hepatocellular carcinoma with hepatitis C virus infection. 2001 , 21, 342-9	27
1035	HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. 2001 , 64, 350-5	97
1034	A model to predict survival in patients with end-stage liver disease. 2001 , 33, 464-70	3267
1033	Radiofrequency ablation for hepatocellular carcinoma: help or hazard?. 2001 , 33, 1336-7	18
1032	Hepatitis B and C in the liver transplant recipient: current understanding and treatment. 2001 , 7, S87-98	26
1031	Changes in hepatitis C-related liver disease in a large clinic population. 2001 , 31, 90-96	4
1030	Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma. 2001 , 92, 59-66	23
1029	Diagnosed with Hepatitis C: a descriptive exploratory study. 2001 , 38, 107-16	51
1028	Natural history of chronic hepatitis C: identifying a window of opportunity for intervention. 2001 , 137, 146-54	1
1027	Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients. 2001 , 11, 373-9	9
1026	Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. 2001 , 48, 843-8	69
1025	Revelance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus. 2001 , 96, 1657-9	16
1024	Clinical guidelines on the management of hepatitis C. 2001 , 49 Suppl 1, 11-21	98

1023	Hepatitis C: a hepatologist's approach to an infectious disease. 2001 , 33, 1728-32	10
1022	Patients' values for health states associated with hepatitis C and physicians' estimates of those values. 2001 , 96, 2730-6	42
1021	Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. 2001 , 221, 740-6	69
1020	Liver Cirrhosis. 2001 ,	
1019	Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. 2002 , 97, 2441-52	79
1018	The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. 2002 , 97, 721-8	37
1017	Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. 2002 , 97, 2886-95	252
1016	[Indications for liver transplantation in chronic liver diseases]. 2002 , 40, 891-902	4
1015	Empirically calibrated model of hepatitis C virus infection in the United States. 2002 , 156, 761-73	97
1014	Cost-effectiveness of cadaveric and living-donor liver transplantation. 2002 , 73, 616-22	56
1013	Hepatitis C: A Clinician's View at the Turn of the Millennium. 2002 , 11, 205-210	
1012	Simulation of hepatitis C based on a mandatory reporting system. 2002 , 14, 25-34	34
1011	Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. 2002 , 162, 2545-56	34
1010	Hepatitis C virus in the etiology of hepatocellular carcinoma. 2002 , 31-42	6
1009	Interferon for the prevention of hepatocellular carcinoma. 2002 , 6, 151-159	
1008	Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. 2002 , 137, 653-7; discussion 657-8	53
1007	Interferon therapy prolonged life expectancy among chronic hepatitis C patients. <i>Gastroenterology</i> , 2002 , 123, 483-91	13.3 200
1006	Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. 2002 , 62, 507-56	56

1005	Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. 2002 , 50, 253-8	42
1004	Liver Transplantation. 2002 , 30, 77-79	1
1003	Does hepatitis C virus cause severe liver disease only in people who drink alcohol?. 2002 , 2, 303-9	22
1002	Prevalence of hepatitis C infection in a large urban hospital-based sample of individuals with spinal cord injury. 2002 , 83, 1620-3	2
1001	Sex hormones and liver cancer. 2002 , 193, 59-63	135
1000	[Treatment of chronic hepatitis C in cirrhosis of the liver]. 2002 , 25, 356-9	
999	[Forecasting the impact of hepatitis C in Catalonia (Spain)]. 2002 , 119, 377-81	3
998	Hepatitis viral aguda. 2002 , 9, 159-167	1
997	Effect of host-related factors on the intensity of liver fibrosis in patients with chronic hepatitis C virus infection. 2002 , 6, 219-24	8
996	Traitement de l'hépatite C. 2002 , 18, 343-352	0
995	Motion - the available treatments for hepatitis C are cost effective: arguments against the motion. 2002 , 16, 710-5	3
994	References. 2002 , 177-248	
993	Hepatitis C and liver transplantation. 2002 , 1, 129-135	6
992	Hepatitis C virus infection in patients on renal replacement therapy. 2002 , 4, 3-12	
991	Variation of hepatitis C virus load, hypervariable region 1 quasispecies and CD81 hepatocyte expression in hepatocellular carcinoma and adjacent non-cancerous liver. 2002 , 68, 188-96	6
990	Course and outcome of hepatitis C. 2002 , 36, S21-S29	526
989	Treatment of patients with hepatitis C and cirrhosis. 2002 , 36, S185-S194	56
988	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. 2002 , 95, 588-95	281

987	Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. 2002 , 22, 479-85	9
986	Hepatitis C in the liver transplant recipient: current understanding and treatment. 2002 , 4, 1253-8	14
985	Progression from chronic hepatitis to hepatocellular carcinoma: natural course and treatments. 2002 , 17 Suppl 3, S434-6	2
984	Is severe liver disease a common outcome for people with chronic hepatitis C?. 2002 , 17, 423-30	71
983	Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. 2002 , 47, 1638-43	49
982	Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the future. 2002 , 36, 252-4	2
981	Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. 2002 , 35, 190-8	136
980	Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. 2002 , 36, 177-85	9
979	Course and outcome of hepatitis C. 2002 , 36, S21-9	479
978	Treatment of patients with hepatitis C and cirrhosis. 2002 , 36, S185-94	38
977	Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. 2002 , 8, 313-22	87
976	Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. 2003 , 38, 420-7	305
975	Validation and refinement of survival models for liver retransplantation. 2003 , 38, 460-9	98
974	Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. 2003 , 38, 493-502	68
973	Can interferon prolong life?. 2003 , 38, 292-4	2
972	The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. 2003 , 9, S28-34	169
971	Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. 2003 , 9, S14-20	23
970	Controversies in the management of hepatitis C virus infection after liver transplantation. 2003 , 9, 1129-44	24

969	Living donor liver transplantation in patients with chronic hepatitis C: timing is everything. 2003 , 9, 1036-9	
968	Hepatitis C antiviral treatment in special populations. 2003 , 2, 101-107	
967	Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. 2003 , 38, 865-76	40
966	Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. 2003 , 38, 1458-67	67
965	Longitudinal risk-based health care for adult survivors of childhood cancer. 2003 , 27, 143-67	86
964	The experience of fatigue for people living with hepatitis C. 2003 , 12, 244-52	47
963	The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. 2003 , 10, 16-22	35
962	High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. 2003 , 10, 205-9	11
961	Predicting progression to cirrhosis in chronic hepatitis C virus infection. 2003 , 10, 285-93	73
960	Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. 2003 , 17, 765-73	19
959	Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. 2003 , 7, 631-50, vii	9
958	An evidence-based approach to studies in cirrhosis and portal hypertension: medical management of mild to moderate ascites. 2003 , 1, 474-9	1
957	Treatment of hepatitis C virus in the coinfecting patient. 2003 , 14, 525-79S	1
956	Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers. 2003 , 38, 1458-1467	83
955	Liver fibrosis -- from bench to bedside. 2003 , 38 Suppl 1, S38-53	1184
954	Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. 2003 , 38, 642-50	60
953	HCV infection, malignancy, and liver transplantation. 2003 , 35, 1032-3	3
952	Hepatocellular carcinoma. 2003 , 362, 1907-17	3580

951	Natural history and epidemiology of hepatitis C. 2003 , 14, 18S-25S	6
950	[Consensus document on indications for liver transplantation. 2002]. 2003 , 26, 355-75	12
949	Hepatitis. 2003 , 30, 81-107	1
948	Treatment of hepatitis C. The 2002 French consensus. 2003 , 52, 1784-7	49
947	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. 2003 , 32, 717-24	110
946	Outcome and management of hepatitis C in liver transplant recipients. 2003 , 37, 807-12	13
945	Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. 2003 , 52, 425-32	157
944	Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. 2003 , 98, 763-70	53
943	Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. 2003 , 98, 679-90	199
942	Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. 2003 , 52, 404-9	85
941	Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. 2003 , 47-51	19
940	Hemoglobinuria with ribavirin treatment. 2003 , 36, 367-8	7
939	Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options. 2003 , 37, 155-63	17
938	Hepatitis C: a review. 2003 , 112, 597-605	5
937	Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. 2003 , 139, 46-50	262
936	High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. 2003 , 17, 479-82	17
935	Detection of anti-HAV antibody with dot immunogold filtration assay. 2003 , 9, 1508-11	10
934	Autoantibodies to CD69 in patients with chronic hepatitis type C: a candidate marker for predicting the response to interferon therapy. 2003 , 46, 56-65	3

933	Etiology of Liver Cirrhosis in Mexico. 2004 , 3, 30-33	59
932	Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 2004 , 10, 3099-102	34
931	The management of chronic viral hepatitis: A Canadian consensus conference 2004. 2004 , 15, 313-26	10
930	The management of chronic viral hepatitis: a Canadian consensus conference 2004. 2004 , 18, 715-28	41
929	Chronic hepatitis C. 2004 , 24 Suppl 2, 1-2	3
928	The natural history of hepatitis C. 2004 , 24 Suppl 2, 3-8	214
927	Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. 2004 , 53, 744-9	323
926	Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. 2004 , 24, 20-9	40
925	Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?. 2004 , 99, 866-72	55
924	Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. 2004 , 99, 860-5	136
923	Atlas of the Liver. 2004 ,	
922	Treatment of chronic HCV infection in compensated and decompensated cirrhosis. 2004 , 19, S94-S98	
921	Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. 2004 , 19, 1159-72	119
920	Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. 2004 , 11, 191-7	13
919	Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. 2004 , 11, 366-74	42
918	A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 2004 , 11, 543-51	9
917	Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C. 2004 , 31, 259-65	13
916	Anesthesia for liver transplant surgery. 2004 , 22, 687-711	57

915	Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. 2004 , 39, 1069-77	60
914	Efficacy of interferon therapy for aged patients with chronic hepatitis C. 2004 , 39, 1123-4	
913	Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. 2004 , 255, 399-408	23
912	Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. 2004 , 11, 148-56	61
911	Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival. 2004 , 76, 107-13	15
910	Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. 2004 , 39, 1239-47	145
909	The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. 2004 , 10, S115-20	513
908	Ascites after liver transplantation--a mystery. 2004 , 10, 654-60	26
907	Rapporto costo-efficacia della terapia peginterferone α 2a + ribavirina in confronto a interferone α 2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati. 2004 , 6, 105-114	3
906	Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. 2004 , 22, 257-65	55
905	Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. 2004 , 33, 527-47, viii	6
904	Screening and treatment for hepatocellular carcinoma. 2004 , 33, 671-91, xi	7
903	Pathogenesis and screening for hepatocellular carcinoma. 2004 , 8, 419-43, viii	12
902	Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. 2004 , 2, 183-97	16
901	Hepatitis C virus antiviral therapy in patients with cirrhosis. 2004 , 33, 549-62, ix	6
900	Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. <i>Gastroenterology</i> , 2004 , 126, 1015-23; discussion 947	13.3 393
899	Introduction: The burden of hepatocellular carcinoma. <i>Gastroenterology</i> , 2004 , 127, S1-4	13.3 49
898	Hepatocellular carcinoma in cirrhosis: incidence and risk factors. <i>Gastroenterology</i> , 2004 , 127, S35-50	13.3 1763

897	Pathogenesis of hepatitis C-associated hepatocellular carcinoma. <i>Gastroenterology</i> , 2004 , 127, S62-71	13,3	178
896	Hepatocellular carcinoma: summary and recommendations. <i>Gastroenterology</i> , 2004 , 127, S319-23	13,3	39
895	Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. 2004 , 99, 1490-6		49
894	Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. 2004 , 27, 7-24		10
893	Treatment of hepatitis C in solid organ transplantation. 2004 , 64, 489-98		8
892	Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. 2004 , 40, 823-30		230
891	Global burden of disease (GBD) for hepatitis C. 2004 , 44, 20-9		375
890	Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. 2004 , 40, 147-54		94
889	Cirrhosis hepática. 2004 , 9, 489-493		
888	Natural history of hepatitis C following liver transplantation. 2004 , 17, 363-71		29
887	Hepatitis C: an emerging epidemic. 2004 , 6, 589-605		0
886	Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. 2004 , 18, F21-5		110
885	The emerging role of gastrointestinal organ transplantation. 2004 , 6, 775-791		1
884	Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. 2004 , 38, S179-86		17
883	Advances in liver transplantation. New strategies and current care expand access, enhance survival. 2004 , 115, 73-6, 79-85		23
882	The surveillance and diagnosis of hepatocellular carcinoma. 2005 , 17, 491-6		23
881	Liver transplantation for hepatocellular carcinoma. 2005 , 19, 147-60		13
880	Staging systems in hepatocellular carcinoma. 2005 , 7, 35-41		183

879	Hepatitis C virus infection. 2005 , 11, 86-94	80
878	Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. 2005 , 25, 772-8	18
877	APASL Abstracts, Bali 2005. 2005 , 25, 1270-1384	1
876	Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. 2005 , 25, 717-22	20
875	Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study. 2005 , 20, 527-35	4
874	Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C. 2005 , 20, 825-32	5
873	Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. 2005 , 12, 421-8	25
872	Pathways of care and resource utilization in a national cohort of patients with transfusion-acquired hepatitis C. 2005 , 12, 618-26	4
871	Serum albumin and platelet count but not portal pressure are predictive of death in patients with Child-Pugh A hepatitis C virus-related cirrhosis. 2005 , 29, 347-52	12
870	Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. 2005 , 41, 40-7	183
869	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. 2005 , 41, 779-89	214
868	AASLD practice guidelines: Evaluation of the patient for liver transplantation. 2005 , 41, 1407-32	575
867	Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. 2005 , 42, 255-62	299
866	Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. 2005 , 42, 711-23	105
865	Management of hepatocellular carcinoma. 2005 , 42, 1208-36	4778
864	Management of hepatitis C virus infection in the setting of liver transplantation. 2005 , 11, 479-89	45
863	Screening for hepatocellular carcinoma. 2005 , 19, 101-18	14
862	Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. 2005 , 6, 112-23	14

861	Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area. 2005 , 174, 37-41	9
860	Treatment of HCV infection with pegylated interferons. 2005 , 4, 49-55	3
859	Antiviral therapy in the liver transplant candidate and recipient. 2005 , 4, 75-82	
858	Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection. 2005 , 50, 1793-803	20
857	Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. 2005 , 142, 105-14	229
856	Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. 2005 , 40 Suppl 5, S263-9	38
855	Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. 2005 , 54, 1014-20	50
854	Outcomes among patients with end-stage liver disease who are coinfectd with HIV and hepatitis C virus. 2005 , 41 Suppl 1, S50-5	14
853	Hepatocellular carcinoma: epidemiology, risk factors, and screening. 2005 , 25, 143-54	326
852	Recent Therapeutic Developments in Hepatic Fibrosis. 2005 , 122-142	
851	Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. 2005 , 100, 2010-8	28
850	The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. 2005 , 100, 313-21	10
849	Liver transplantation for hepatitis C virus related liver disease. 2005 , 81, 765-71	2
848	EMPIRICAL DATA AND MATHEMATICAL STRUCTURES IN THE EPIDEMIC MODELING OF PARENTERAL HEPATITIS IN ITALY. 2005 , 08, 33-58	1
847	Risk factors for hepatitis B and C in multi-transfused patients in Uruguay. 2005 , 34 Suppl 2, S69-74	25
846	Treatment of hepatitis C in the patient with decompensated cirrhosis. 2005 , 3, S106-12	14
845	Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. 2005 , 3, 75-84	71
844	Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. 2005 , 3, S141-3	52

843	Treatment of hepatitis C in patients who have decompensated cirrhosis. 2005 , 9, 473-86, viii	11
842	Influence of recent advances in medical management on clinical outcomes of cirrhosis. 2005 , 80, 1501-8	39
841	Management of hepatitis C virus in special populations: patient and treatment considerations. 2005 , 3, 311-8	27
840	Prevention of hepatocellular carcinoma. 2005 , 9, 329-46, viii	46
839	Natural history of hepatitis C. 2005 , 9, 383-98, vi	281
838	Is cirrhosis an inevitable consequence of chronic hepatitis C virus infection?. 2005 , 3, 840-2	11
837	Treatment of hepatitis C after liver transplantation. 2005 , 9, 579-600, vi	31
836	Treatment of hepatitis C: critical appraisal of the evidence. 2005 , 6, 399-408	17
835	Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. 2005 , 40, 688-96	22
834	Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. 2005 , 42, 639-45	83
833	Management of cirrhosis due to chronic hepatitis C. 2005 , 42 Suppl, S65-74	19
832	Should we treat patients with chronic hepatitis C on the waiting list?. 2005 , 42, 456-62	27
831	MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. 2005 , 42, 820-5	83
830	High mortality rate in patients with advanced liver disease independent of exposure to general anesthesia. 2005 , 17, 172-6	5
829	Value of computed tomography and magnetic resonance imaging for assessing severity of liver cirrhosis secondary to viral hepatitis. 2005 , 54, 400-7	34
828	Treatment of hepatitis C. 2005 , 118, 808-15	70
827	[Early diagnosis of liver cancer]. 2005 , 28, 292-7	4
826	[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]. 2005 , 23, 32-40	4

825	Management of ascites in cirrhosis. 2005 , 9, 715-32, viii		33
824	Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. 2005 , 3, 1034-42		26
823	Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. 2005 , 100, 2338-54		62
822	Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. 2006 , 4, 1378-84		51
821	Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. 2006 , 27, 748-57		228
820	Improving anti-hepatitis C virus therapy. 2006 , 6, 923-33		16
819	Treatment of hepatitis C infection. 2006 , 35, 463-86		10
818	Palliative care for patients with end-stage liver disease ineligible for liver transplantation. 2006 , 35, 201-19		42
817	Diagnosis and management of allograft failure. 2006 , 10, 407-35, x		24
816	Chronic hepatitis C and screening for hepatocellular carcinoma. 2006 , 10, 735-52		2
815	American Gastroenterological Association technical review on the management of hepatitis C. <i>Gastroenterology</i> , 2006 , 130, 231-64; quiz 214-7	13.3	312
814	Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. 2006 , 66, 155-74		66
813	Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. 2006 , 41, 1395-463		36
812	Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. 2006 , 38, 445-51		10
811	Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. 2006 , 38, 497-505		24
810	Perinatal hepatitis C virus infection: diagnosis and management. 2006 , 91, 781-5		50
809	The changing epidemiology and natural history of hepatitis C virus infection. 2006 , 10, 697-715		71
808	Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. 2006 , 55, 1332-8		80

807	Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. 2006 , 44, 47-55	307
806	Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. 2006 , 44, 455-61	69
805	Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. 2006 , 44, 217-31	1844
804	Part II: the gastroenterologist. 2006 , 44, 657-8	3
803	Hepatitis C. 2006 , 461-471	2
802	Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. 2006 , 20, 725-34	4
801	Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. 2006 , 20, 257-60	31
800	Outpatient management of cirrhosis: a narrative review. 2006 , 99, 600-6	12
799	Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. 2006 , 40, 942-8	43
798	Effect of nonviral factors on hepatitis C recurrence after liver transplantation. 2006 , 244, 563-71	9
797	Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation. 2006 , 81, 392-7	17
796	Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome. 2006 , 20, 465-70	17
795	Treatment and prognostic factors in patients with hepatocellular carcinoma. 2006 , 26, 680-7	42
794	Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. 2006 , 26, 650-9	20
793	Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. 2006 , 13, 409-14	95
792	Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. 2006 , 13, 652-8	32
791	HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. 2006 , 13, 762-9	58
790	Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. 2006 , 13, 811-20	34

789	Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C. 2006 , 19, 1047-54	14
788	Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. 2006 , 100, 767-74	44
787	Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. 2006 , 13, 457-65	25
786	Management of patients with chronic hepatitis C infection. 2006 , 6, 20-6	16
785	The SHAP-hyaluronan complex in serum from patients with chronic liver diseases caused by hepatitis virus infection. 2006 , 34, 178-86	11
784	Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. 2006 , 8, 46-52	17
783	Management of recurrent viral hepatitis B and C after liver transplantation. 2006 , 8, 60-6	3
782	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. 2006 , 5, 114-120	
781	Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1. 2006 , 37, 663-73	12
780	[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. 2006 , 30, 1281-95	3
779	Reversal of hepatic fibrosis -- fact or fantasy?. 2006 , 43, S82-8	308
778	Noninvasive measures of liver fibrosis. 2006 , 43, S113-20	257
777	Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. 2006 , 43, 581-91	33
776	The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. 2006 , 43, 1303-10	436
775	Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. 2006 , 44, 1598-606	42
774	Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. 2006 , 44, 1511-7	382
773	The challenge of progressive hepatitis C following liver transplantation. 2006 , 12, 19-21	6
772	Hepatocellular carcinoma in the setting of liver transplantation. 2006 , 12, 1028-36	24

771	Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. 2006 , 78, 459-65	47
770	Therapie des hepatozellulären Karzinoms. 2006 , 27, 171-177	
769	[Treatment of hepatocellular carcinoma]. 2006 , 44, 43-9	8
768	Hepatic Fibrosis and Cirrhosis. 2006 , 87-109	7
767	Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center. 2006 , 49, 82-90	24
766	Multivariate and univariate analysis of prognostic factors following resection in HCC: the Birmingham experience. 2006 , 23, 103-9	19
765	The clinical outcome of small (. 2007 , 102, 1654-9	23
764	Strategies for the management of hepatocellular carcinoma. 2007 , 4, 424-32	222
763	Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. 2007 , 42, 867-77	10
762	Long-term effects of interferon-based therapy for chronic hepatitis C. 2007 , 72 Suppl 1, 16-23	29
761	Aktuelle Diagnostik und Therapie des hepatozellulären Karzinoms. 2007 , 3, 115-132	
760	Changing treatment paradigms: hepatitis C virus in HIV-infected patients. 2007 , 21, 154-68	9
759	Acute and Chronic Viral Hepatitis. 369-446	
758	Diagnosis and management of cirrhosis in coinfecting patients. 2007 , 45 Suppl 2, S38-46; discussion S66-7	13
757	The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. 2007 , 19, 733-9	8
756	Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. 2007 , 41, 103-10	64
755	Hepatitis C virus infection: a current review. 2007 , 20, 21-5	1
754	Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 2007 , 46, 297-303	25

753	Modelling the hepatitis C virus epidemic in Australia. 2007 , 91, 228-35	109
752	Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. 2007 , 46, 206-12	168
751	The natural history of hepatitis C with severe hepatic fibrosis. 2007 , 47, 37-45	36
750	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. 2007 , 47, 484-91	84
749	Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. 2007 , 37, 793-800	12
748	Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. 2007 , 14, 228-38	43
747	Viral Hepatitis. 819-956	
746	A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C. 2007 , 7, 577-95	3
745	The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. 2007 , 111-121	7
744	Liver Immunology. 2007 ,	4
743	Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. 2007 , 5, 502-7	37
742	Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. 2007 , 25, 963-77	34
741	Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. 2007 , 5, 938-45, 945.e1-4	172
740	Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. 2007 , 5, 932-7	106
739	Surveillance for hepatocellular carcinoma and early diagnosis. 2007 , 11, 817-37, viii	21
738	Liver transplantation(). 2007 , 10, 28-45	5
737	[Candidate selection for liver transplantation]. 2007 , 30, 42-53	7
736	[Does antiviral therapy improve the clinical course of cirrhosis due to hepatitis C virus infection?]. 2007 , 30, 85-92	

735	[Updated guide for diagnosis, staging and treatment of hepatocellular carcinoma]. 2007 , 128, 741-8	3
734	Long-term outcome after interferon therapy in patients with chronic hepatitis C.. 2007 , 6, 267-269	2
733	Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 2007 , 45, 579-87	517
732	Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. 2007 , 46, 622-30	154
731	Hepatitis C virus and human immunodeficiency virus: the un-won battle. 2007 , 46, 611-4	3
730	Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. 2007 , 46, 1350-6	141
729	Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates. 2007 , 13, 206-14	38
728	Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. 2007 , 13, 1521-31	109
727	Surveillance and diagnosis for hepatocellular carcinoma. 2007 , 13, S2-12	9
726	Indications of liver transplantation in patients with complications of cirrhosis. 2007 , 21, 175-90	20
725	Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. 2007 , 22, 669-75	68
724	The best candidates for transarterial chemotherapy in patients with hepatocellular carcinoma awaiting liver transplantation: a cohort-based characterization of dropout times. 2007 , 26, 87-94	3
723	Review article: the treatment of hepatitis C virus recurrence after liver transplantation. 2007 , 26, 127-40	18
722	Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin. 2008 , 28, 407-11	7
721	Hepatitis C: a clinical review. 2008 , 14, 10-4	49
720	Replacement of hystological findings: serum hyaluronic acid for fibrosis, high-sensitive C-reactive protein for necroinflamation in chronic viral hepatitis. 2007 , 61, 438-43	11
719	Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. 2007 , 27, 813-24	10
718	Viral hepatitis and hepatocellular carcinoma. 2007 , 38, 612-20	43

717	Screening for hepatocellular carcinoma. 2007 , 37 Suppl 2, S152-65	16
716	Liver transplantation. 2007 , 35, 112-115	
715	Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. 2007 , 52, 570-8	24
714	Cryoglobulinemia related to hepatitis C virus infection. 2007 , 52, 897-907	29
713	Effects of hepatitis C-induced liver fibrosis on survival in kidney transplant candidates. 2007 , 52, 2501-7	16
712	Hepatitis C and hepatocellular carcinoma. 2007 , 6, 87-90	
711	Hepatitis C virus infection in HIV-infected patients. 2007 , 3, 469-76	9
710	Traitement de la cirrhose virale C. 2007 , 1, 59-62	
709	Früherkennung des hepatozellulären Karzinoms. 2007 , 2, 356-364	1
708	Systemic therapy of hepatocellular carcinoma: are we making progress?. 2008 , 25, 1089-104	61
707	Hepatitis C in India. 2008 , 33, 465-73	70
706	Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. 2008 , 2, 17-30	129
705	Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. 2008 , 43, 720-8	59
704	Changing management and outcome of hepatocellular carcinoma: evaluation of 501 patients treated at a single comprehensive center. 2008 , 98, 81-8	12
703	Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. 2008 , 47, 789-98	139
702	The natural history of recurrent hepatitis C and what influences this. 2008 , 14 Suppl 2, S36-44	212
701	Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. 2008 , 23, 437-44	40
700	Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?. 2008 , 103, 1412-3	17

699	Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. 2008 , 27, 1240-52		23
698	Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. 2008 , 8, 1-18		
697	The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. 2008 , 15, 797-808		25
696	Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. 2008 , 375, 580-91		12
695	TaqMan real-time PCR assay for specific detection of <i>Opisthorchis viverrini</i> DNA in Thai patients with hepatocellular carcinoma and cholangiocarcinoma. 2008 , 119, 217-24		18
694	The global impact of hepatic fibrosis and end-stage liver disease. 2008 , 12, 733-46, vii		218
693	Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. <i>Gastroenterology</i> , 2008 , 134, 8-14	13.3	128
692	Indications for liver transplantation. <i>Gastroenterology</i> , 2008 , 134, 1764-76	13.3	138
691	Complications of cirrhosis. 2008 , 54, 445-56		23
690	Cirrosis hepática. 2008 , 10, 685-690		
689	Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. 2008 , 38, 37-51		250
688	Feasibility of diagnosing and staging liver fibrosis with diffusion weighted imaging. 2008 , 23, 183-6		15
687	Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. 2008 , 6, 1418-24		173
686	Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. 2008 , 12, 209-18		12
685	MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. 2008 , 247, 311-30		303
684	Molecular Targeting in Hepatocellular Carcinoma. 2008 , 165-210		1
683	Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. 2008 , 51 Suppl 1, 17-26		102
682	Impact of interferon therapy after curative treatment of hepatocellular carcinoma. 2008 , 75 Suppl 1, 30-41		21

681	Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. 2008 , 98, 1166-75	102
680	Factors influencing Hepatitis C virus sero-prevalence among blood donors in north west Pakistan. 2008 , 29, 207-25	17
679	Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. 2008 , 14, 470-7	162
678	Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. 2008 , 143, 1082-90	116
677	Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. 2008 , 112, 542-50	71
676	Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis. 2008 , 42, 734-7	19
675	Liver Transplantation. 235-255	
674	Complications of Cirrhosis. 215-234	1
673	Chronic Hepatitis C. 39-60	1
672	Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. 2008 , 42, 839-43	64
671	Hepatocellular carcinoma: management of an increasingly common problem. 2008 , 21, 266-80	128
670	Comparison of liver biopsy and transient elastography based on clinical relevance. 2008 , 22, 753-7	16
669	Mortality trends for liver cancer in Mexico from 2000 to 2006: Original Article. 2008 , 7, 226-229	20
668	The natural course of HCV infection and the need for treatment. 2008 , 7, 114-119	20
667	Sorafenib, a systemic therapy for hepatocellular carcinoma. 2008 , 7, 46-51	25
666	AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. 2008 , 7, 350-357	125
665	Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. 2009 , 13, 191-9	11
664	Managing hepatitis C in liver transplant patients with recurrent infection. 2009 , Volume 1, 1-14	

663	Liver transplantation. 2009 , 3, 145-65	56
662	Hepatitis C Virus. 2009 , 1215-1240	
661	Current status of therapy for hepatocellular carcinoma. 2009 , 2, 45-57	11
660	[Metabolic disturbances in liver cirrhosis (part 1)--hepatic osteopathy and malnutrition]. 2009 , 134, 2461-4	3
659	Hepatocellular carcinoma--epidemiological trends and risk factors. 2009 , 27, 80-92	355
658	Recent advances in viral hepatitis. 2009 , 9, 613-6	5
657	Modelling and calibration of the hepatitis C epidemic in Australia. 2009 , 18, 253-70	14
656	Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. 2009 , 49, 1274-82	62
655	Diagnosis, management, and treatment of hepatitis C: an update. 2009 , 49, 1335-74	2284
654	Increased liver-related mortality to hepatitis C viremia defined on the 20th anniversary of its identification. 2009 , 50, 349-51	3
653	Treatment of hepatitis C in liver transplant recipients. 2009 , 15, 126-35	27
652	The natural history of hepatitis C cirrhosis after liver transplantation. 2009 , 15, 1063-71	80
651	The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. 2009 , 44 Suppl 19, 96-101	165
650	Portosystemic shunts in a large cohort of patients with liver cirrhosis: detection rate and clinical relevance. 2009 , 44, 76-83	54
649	External validation of the platelet count/spleen diameter ratio for the diagnosis of esophageal varices in hepatitis C virus-related cirrhosis. 2009 , 54, 654-60	40
648	Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. 2009 , 54, 1758-63	115
647	Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. 2009 , 54, 2530-7	28
646	When to treat and the benefits of treating hepatitis C in patients with haemophilia. 2009 , 15, 20-32	7

645	Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. 2009 , 16, 650-8		72
644	Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. 2009 , 16, 802-13		15
643	Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India. 2009 , 24, 581-7		15
642	Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. 2009 , 22, 172-81		33
641	Clinical and histological impact of previous hepatitis B virus infection in patients with chronic hepatitis C. 2009 , 29, 133-40		7
640	Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. 2009 , 29, 502-10		234
639	Oxidative stress and thyroid hormones in patients with liver diseases. 2009 , 20, 703-8		47
638	Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. 2009 , 18, 233-52		16
637	Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area. 2009 , 41, 509-15		11
636	Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. 2009 , 104, 1147-58		125
635	Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. 2009 , 27, 341-54		22
634	Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. 2009 , 25, 171-80		35
633	Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. <i>Gastroenterology</i> , 2009 , 136, 138-48	13.3	481
632	Hepatitis C and hepatocellular carcinoma: grist for the mill. <i>Gastroenterology</i> , 2009 , 136, 39-42	13.3	4
631	Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. <i>Gastroenterology</i> , 2009 , 137, 1986-94	13.3	29
630	Management of ascites. 2009 , 69, 1739-60		12
629	Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. 2009 , 41, 689-99		43
628	Clinical implications of alpha-fetoprotein in chronic hepatitis C. 2009 , 108, 210-8		34

627	Care of the cirrhotic patient. 2009 , 13, 331-40	4
626	Liver transplantation: from Child to MELD. 2009 , 93, 931-50, ix	22
625	Parenchymal extinction: coagulation and hepatic fibrogenesis. 2009 , 13, 117-126	67
624	Surgery in the patient with liver disease. 2009 , 13, 211-31	70
623	PillCam ESO versus esophagogastroduodenoscopy in esophageal variceal screening: A decision analysis. 2009 , 43, 975-81	13
622	The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2. 2009 , 48, 1337-42	8
621	Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. 2009 , 43, 758-64	36
620	Consensus Report of the Third International Forum for Liver Magnetic Resonance Imaging. 2010 , 45, S1-S10	3
619	Anatomical segmental and subsegmental resection of the liver for hepatocellular carcinoma: a new approach by means of ultrasound-guided vessel compression. 2010 , 251, 229-35	73
618	Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. 2010 , 22, 474-80	26
617	Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection: a case report and review of literature. 2010 , 3, 237-42	6
616	Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. 2010 , 28, 362-8	22
615	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. 2010 , 4, 439-74	825
614	Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. 2010 , 4, 634-40	55
613	The healthcare burden imposed by liver disease in aging Baby Boomers. 2010 , 12, 1-6	31
612	Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). 2010 , 55, 484-95	24
611	A review of the treatment of chronic hepatitis C virus infection in cirrhosis. 2010 , 32, 2117-38	80
610	Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. 2010 , 51, 2069-76	151

609	Long-term effects of sustained virologic response on the development of esophageal varices in compensated cirrhosis: "is the bang worth the buck?". 2010 , 51, 1891-3	
608	Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. 2010 , 16, 748-59	38
607	The influence of age in decision-making of patients with HCC. 2010 , 10,	78
606	Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction: a focus on recent advances in proteomics. 2010 , 4, 782-93	31
605	Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. 2010 , 32, 344-55	149
604	Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. 2010 , 2, 87-96	5
603	Hepatocellular carcinoma [diagnostic dilemmas. 2010 , 2, 61-67	
602	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. 2010 , 56, e1-48	160
601	Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. 2010 , 59, 1401-9	81
600	Long-term effects of antiviral therapy in patients with chronic hepatitis C. 2010 , 2010, 562578	4
599	Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment. 2010 , 105, 2174-6	5
598	Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. 2010 , 78 Suppl 1, 17-23	18
597	Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus. 2010 , 78 Suppl 1, 11-6	6
596	[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. 2010 , 48, 289-351	123
595	Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. 2010 , 30, 3-16	298
594	Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. 2010 , 23, 276-83	36
593	Chronic hepatitis C of 28 years' duration characterized by early development of stage 2 (of 4) fibrosis but no significant progression over the subsequent 18 years. 2010 , 30, 302-9	1
592	A 70-year-old woman with 10 years of markedly elevated alpha-fetoprotein measurements. 2010 , 30, 99-106	1

591	Management of untreated and nonresponder patients with chronic hepatitis C. 2010 , 30, 348-60		3
590	Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. 2010 , 8, 924-33; quiz e117		93
589	An overview about hepatitis C: a devastating virus. 2010 , 36, 91-133		83
588	Viral Infections by Hepatotropic Viruses. 2010 , 671-821		
587	The changing pattern of epidemiology in hepatocellular carcinoma. 2010 , 42 Suppl 3, S206-14		409
586	Hepatocellular carcinoma: New and emerging risks. 2010 , 42 Suppl 3, S215-22		22
585	Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. 2010 , 42 Suppl 3, S287-92		4
584	Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. <i>Gastroenterology</i> , 2010 , 138, 136-46	13.3	76
583	Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. <i>Gastroenterology</i> , 2010 , 138, 513-21, 521.e1-6	13.3	720
582	Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. <i>Gastroenterology</i> , 2010 , 138, 922-31.e1	13.3	39
581	Hepatitis C virus replication and potential targets for direct-acting agents. 2010 , 3, 43-53		12
580	Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. 2010 , 52, 652-7		260
579	Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. 2010 , 53, 616-23		39
578	Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. 2010 , 42, 3647-51		2
577	Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. 2010 , 28, 6367-73		155
576	Chapter 2: Diagnosis and surveillance. 2010 , 40, 16-47		14
575	Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan. 2010 , 40, 989-96		8
574	Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. 2010 , 109, 39-55		14

573	Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. 2010 , 105, 2164-72; quiz 2173	53
572	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. 2011 , 11, 301-13	13
571	Care of the liver transplant candidate. 2011 , 15, 779-806	1
570	Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. 2011 , 9, 602-8.e1	53
569	Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?. 2011 , 35, 455-64	3
568	Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2. 2011 , 46, 79-90	3
567	Advances in hepatobiliary surgery. 2011 , 1, 141-146	
566	Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. 2011 , 14, 1068-77	48
565	Clinical practice. Chronic hepatitis C infection. 2011 , 364, 2429-38	333
564	Chronic Liver Failure. 2011 ,	2
563	No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. 2011 , 9, 786-792.e1	10
562	Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making. 2011 , 1, 27-33	3
561	Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. 2011 , 3, 21-8	4
560	All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. 2011 , 17, 531-46	127
559	A comprehensive analysis of the dynamic biological networks in HCV induced hepatocarcinogenesis. 2011 , 6, e18516	24
558	Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. 2011 , 45, 906-11	53
557	The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. 2011 , 25, 899-904	56
556	Primary Malignant Neoplasms of the Liver. 2011 , 681-703	4

555	Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. 2011 , 18, 542-8	3
554	Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis. 2011 , 18, 493-505	17
553	Common complications of cirrhosis: do we follow too often the 'Casablanca strategy'?. 2011 , 31, 1598-600	3
552	Evolving epidemiology of hepatitis C virus. 2011 , 17, 107-15	948
551	Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. 2011 , 65, 182-8	19
550	The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α b and ribavirin. 2011 , 43, 3824-8	7
549	Chronic hepatitis C. 2011 , 5, 117-32	22
548	Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. 2011 , 56, 578-85	51
547	Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. 2011 , 56, 1853-61	35
546	Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. 2011 , 13, 842-8	20
545	Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. 2011 , 46, 799-808	24
544	Fibrosis in chronic viral hepatitis. 2011 , 25, 219-30	20
543	Progression of liver cirrhosis to HCC: an application of hidden Markov model. 2011 , 11, 38	24
542	Evaluation of fibrosis in cirrhotic elderly patients with HCC. 2011 , 11, A47	78
541	Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. 2011 , 34, 88-94	80
540	Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. 2011 , 53, 1100-8	44
539	A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. 2011 , 54, 396-405	121
538	Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. 2011 , 54, 1527-37	23

537	Recurrent Disease Following Liver Transplantation. 2011 , 1152-1171	
536	Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. 2011 , 52, 889-900	187
535	The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. 2011 , 2011, 314301	2
534	Circulating Plasma Albumin mRNA as a Predictor of Liver Injury in Chronic Hepatitis C and Hepatocellular Carcinoma. 2011 , 258-267	
533	Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. 2011 , 32, 71-5	17
532	Pretransplant Evaluation and Care. 2012 , 837-852	
531	Treatment of patients with HCV related cirrhosis: many rewards with very few risks. 2012 , 12, 361-8	7
530	Management of HBV- and HCV-induced end stage liver disease. 2012 , 61 Suppl 1, i59-67	21
529	SASLT practice guidelines: management of hepatitis C virus infection. 2012 , 18 Suppl, S1-32	5
528	Resource use and cost of hepatitis C-related care. 2012 , 24, 1191-8	18
527	Management of HCC. 2012 , 56 Suppl 1, S75-87	438
526	Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. 2012 , 42, 22-32	7
525	Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients. 2012 , 57, 3265-70	15
524	Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. 2012 , 82, e529-35	51
523	Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. 2012 , 10, 1412-7	31
522	Causes of and prevention strategies for hepatocellular carcinoma. 2012 , 39, 374-83	42
521	Hepatocellular Carcinoma. 2012 , 1005-1031	1
520	Care of the cirrhotic patient. 2012 , 26, 979-94	3

519	Cost-effectiveness and population outcomes of general population screening for hepatitis C. 2012 , 54, 1259-71	81
518	Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma. 2012 , 32, 1382-90	24
517	Basic answers to complicated questions for the course of chronic hepatitis C treatment. 2012 , 6, 371-82	1
516	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. 2012 , 56, 602-8	25
515	[Current indications for triple therapy in hepatitis C virus infection]. 2012 , 35, 266-77	
514	Surveillance for hepatocellular carcinoma. 2012 , 39, 384-98	50
513	Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. 2012 , 13, 49-53	15
512	Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. 2012 , 15, 894-906	16
511	Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. 2012 , 15, 876-86	5
510	[Pathogenic interactions between alcohol and hepatitis C]. 2012 , 138, 627-32	4
509	Liver and Gall Bladder. 2012 , 275-288	
508	Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients. 2012 , 24, 323-331	28
507	Natural history of HCV infection. 2012 , 6, 684-95	17
506	Chronic Hepatitis C Virus. 2012 ,	2
505	Pancreas and liver. 242-266	
504	Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. 2012 , 11, 855-861	32
503	The epidemiologic burden of hepatitis C virus infection in Latin America. 2012 , 11, 623-635	26
502	Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. 2012 , 6, 285-95	16

501	Hepatic Fibrosis and Cirrhosis. 2012 , 64-85	8
500	[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis]. 2012 , 60, 306-14	7
499	Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. 2012 , 142-156	1
498	Liver fibrosis: mechanisms of immune-mediated liver injury. 2012 , 9, 296-301	101
497	Hepatitis C viral infection in patients with cirrhosis. 2012 , 1, 65-68	
496	Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. 2012 , 47, 823-33	8
495	Future treatment of patients with HCV cirrhosis. 2012 , 32 Suppl 1, 113-9	21
494	The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. 2012 , 107, 614-23	24
493	Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α -fetoprotein levels. 2012 , 42, 254-63	3
492	Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. 2012 , 42, 376-84	34
491	SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin. 2013 , 33, 1110-6	7
490	Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. 2013 , 13, 190	43
489	Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. 2013 , 48, 535-43	2
488	Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. 2013 , 58, 1459-76	35
487	Natural History of HCV-induced Liver Disease. 2013 , 12, 251-260	1
486	Effect of human leukocyte antigen class I and II alleles on hepatitis C viral load among chronic hepatitis C patients in Southern Taiwan. 2013 , 74, 978-82	2
485	The natural history of compensated HCV-related cirrhosis: a prospective long-term study. 2013 , 58, 434-44	59
484	Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil. 2013 , 11, 25	9

483	Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. 2013 , 31, 919-31	25
482	Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment. 2013 , 14, 94-8	10
481	The model for end-stage liver disease (MELD) predicts early and late outcomes of cardiovascular operations in patients with liver cirrhosis. 2013 , 96, 1672-8	28
480	Thyroid disease in chronic hepatitis C infection treated with combination interferon- α and ribavirin: management strategies and future perspective. 2013 , 19, 292-300	9
479	Cirrhosis Regression and Subclassification. 2013 , 6, 295-309	10
478	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. 2013 , 36, 555-64	1
477	Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. 2013 , CD003617	17
476	The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. 2013 , 58, 54-64	65
475	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. 2013 , 58, 1548-57	89
474	All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. 2013 , 20, 847-57	50
473	Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. 2013 , 11, 65-78	30
472	The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. 2013 , 37, 254-61	14
471	A comparison of a deterministic and stochastic model for hepatitis C with an isolation stage. 2013 , 7, 276-301	13
470	Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. 2013 , 16, 973-86	54
469	Cost-effectiveness of screening for chronic hepatitis C infection in the United States. 2013 , 56, 1382-93	48
468	Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. 2013 , 58, 2691-704	26
467	Evaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis C treatment completion rates at a veterans affairs medical center. 2013 , 2013, 653976	1
466	A multidisciplinary approach: group dynamics. 2013 , 47 Suppl, S27-9	6

465	Epidemiology of hepatocellular carcinoma: consider the population. 2013 , 47 Suppl, S2-6	803
464	Evaluation of the hepatitis C virus-infected patient: the initial encounter. 2013 , 56, 853-60	6
463	Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. 2013 , 5, 1-10	11
462	Current approaches to the management of hepatitis C. 2013 , 24, 30-34	
461	Hepatitis C infection and outcomes in the Scottish haemophilia population. 2013 , 19, 870-5	7
460	Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection. 2013 , 33, 420-7	17
459	Compensated cirrhosis, same outcomes no matter which continent. 2013 , 58, 1511-3	
458	Frequent coinfection with hepatitis among HIV-positive patients in Urumqi, China. 2013 , 12, 58-61	7
457	Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy. 2013 , 108, 1112-22	35
456	Could near-infrared Raman spectroscopy be correlated with the METAVIR scores in liver lesions induced by hepatitis C virus?. 2013 ,	2
455	District general hospital networks can provide safe and effective hepatitis C treatment: results of a 5-year audit. 2013 , 25, 942-7	1
454	A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. 2013 , 25, 601-5	2
453	Prevalence and factors associated with HCV infection among elderly individuals in a southern Brazilian city. 2013 , 46, 281-7	2
452	Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. 2013 , 8, e51926	41
451	Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. 2014 , 9, e90295	17
450	A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. 2014 , 9, e93601	4
449	Transmission Dynamics of Hepatitis C with Control Strategies. 2014 , 2014, 1-18	7
448	Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study. 2014 , 20, 5519-26	6

447	Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. 2014 , 20, 11069-79	18
446	Pathology Features and Molecular Genetic Mechanisms of Hepatocellular Carcinoma Development in Patients with Hepatitis C Associated Liver Cirrhosis. 2014 , 03,	
445	Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load. 2014 , 44, 1277-85	9
444	The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages. 2014 , 8, 527-39	5
443	Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness. 2014 , 16, 1	8
442	HCV: Fibrosis Progression. 2014 , 13, 265-272	1
441	The Investigation of HCV RNA in Tear Fluid and Aqueous Humor in Patients with Anti-HCV Antibody Positive Who Underwent Cataract Surgery. 2016 , 24, 297-301	5
440	Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. 2014 , 34, e308-16	4
439	Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. 2014 , 21, 357-65	10
438	. 2014 ,	
437	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. 2014 , 44, 983-92	3
436	HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN α and Ribavirin: a randomized controlled trial. 2014 , 21, 458-65	15
435	Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia. 2014 , 17, 792-800	11
434	Hepatocellular Carcinoma. 2014 ,	
433	Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection. 2014 , 49, 1567-77	14
432	Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. 2014 , 60, 37-45	88
431	Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. 2014 , 59, 1144-65	502
430	Surgery in patients with portal hypertension: a preoperative checklist and strategies for attenuating risk. 2014 , 18, 477-505	19

429	Abdominal Ultrasound for Surgeons. 2014,	1
428	Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. 2014, 60, 530-7	98
427	Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. 2014, 43, 17-25	9
426	Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. 2014, 34, 1176-83	23
425	Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. 2014, 58, 3485-95	53
424	Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. 2014, 8, 352-64	1
423	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. 2014, 21, 568-77	18
422	A model of bi-mode transmission dynamics of hepatitis C with optimal control. 2014, 133, 91-109	9
421	The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. 2014, 5, 673-91	113
420	A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. 2014, 14, 170	9
419	Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study. 2014, 18, 48-52	11
418	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. 2014, 61, 482-91	18
417	The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. 2014, 184, 574-83	63
416	Hepatitis B and C. 2014, 30, 149-67	4
415	Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. 2014, 60, 1118-26	18
414	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. 2014, 60, 191-6	30
413	Management of end-stage liver disease. 2014, 98, 119-52	27
412	Platelet count/spleen diameter ratio to predict esophageal varices in Mexican patients with hepatic cirrhosis. 2014, 20, 2079-84	26

411	Cost-effectiveness of boceprevir co-administration versus pegylated interferon- α 2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore. 2015 , 20, 209-16	12
410	How to define transarterial chemoembolization failure or refractoriness: a European perspective. 2014 , 3, 119-24	90
409	Genetics of Alcoholic Liver Disease. 2015 , 35, 361-74	29
408	AST-to-Platelet Ratio Index (APRI) as Marker in Liver Disease. 2015 , 1-16	
407	Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea. 2015 , 30, 1281-7	15
406	Hepatocellular Carcinoma. 2015 , 2146-2165	
405	Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. 2015 , 7, 1843-55	24
404	Hepatocellular carcinoma: From diagnosis to treatment. 2015 , 7, 1020-9	108
403	Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. 2015 , 6, 114-9	10
402	Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria. 2015 , 15, 728-36	6
401	Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. 2016 , 8, 15-21	7
400	Hepatitis C. 2015 , 1904-1927.e9	4
399	Psychosocial Status of Liver Transplant Candidates in Iran and Its Correlation with Health-Related Quality of Life and Depression and Anxiety. 2015 , 2015, 329615	6
398	Viral Hepatitis. 2015 , 1439-1468.e7	4
397	Hepatocellular carcinoma in Asia: Prevention strategy and planning. 2015 , 7, 1708-17	67
396	Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C. 2015 , 14, 36-45	0
395	Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?. 2015 , 7, 1936-52	15
394	The hepatitis C treatment revolution: how to avoid Asia missing out. 2015 , 1, 272-275	3

- 393 Advances in HCV Therapy. **2015**,
- 392 Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. **2015**, 30, 1183-9 67
- 391 A retrospective analysis of cirrhotic patients receiving Chinese herbal medicine in addition to conventional care: Survival and safety. **2015**, 7, 143-150 5
- 390 Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?. **2015**, 9, 559-66 13
- 389 Anticancer effect of rosiglitazone in rats treated with N-nitrosodiethylamine via inhibition of DNA synthesis: an implication for hepatocellular carcinoma. **2015**, 5, 68385-68391 8
- 388 Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis. **2015**, 37, 1529-40 8
- 387 Potential role of thymosin Beta 4 in liver fibrosis. **2015**, 16, 10624-35 16
- 386 Management of HCV in cirrhosis-a rapidly evolving landscape. **2015**, 17, 443 3
- 385 Natural History of Hepatitis C. **2015**, 120-130
- 384 Correlation between METAVIR scores and Raman spectroscopy in liver lesions induced by hepatitis C virus: a preliminary study. **2015**, 30, 1347-55 4
- 383 Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. **2015**, 18, 678-90 18
- 382 Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. **2015**, 15, 156 4
- 381 Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study. **2015**, 87, 1199-206 8
- 380 Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. **2015**, 162, 397-406 263
- 379 The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. **2015**, 61, 157-68 110
- 378 Computer-aided assessment of hepatic contour abnormalities as an imaging biomarker for the prediction of hepatocellular carcinoma development in patients with chronic hepatitis C. **2015**, 84, 811-5 3
- 377 Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. **2015**, 15, 98 37
- 376 Shear-wave elasticity imaging of a liver fibrosis mouse model using high-frequency ultrasound. **2015**, 62, 1295-307 8

375	Outcomes in pediatric hepatitis C transplant recipients: analysis of the UNOS database. 2015 , 19, 153-63	7
374	Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach. 2015 , 15, 297	18
373	Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. 2015 , 19, 591-604, v	
372	Natural History of Hepatitis C. 2015 , 44, 717-34	121
371	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. 2015 , 64, 322-31	28
370	Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. 2015 , 22, 376-83	34
369	Impact of delayed diagnosis time in estimating progression rates to hepatitis C virus-related cirrhosis and death. 2015 , 24, 693-710	7
368	Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. 2015 , 64, 1800-9	46
367	Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. 2015 , 61, 227-37	53
366	Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. 2015 , 64, 1277-88	41
365	Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients. 2015 , 22, 18-24	17
364	Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. 2015 , 22, 175-83	16
363	Texture-based classification of liver fibrosis using MRI. 2015 , 41, 322-8	44
362	Hepatitis C Virus. 2016 , 1313-1345	
361	[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis]. 2016 , 67, 137-41	
360	Hepatitis C: A New Future Everyday. 2016 , 27, 74-77	
359	Patologia sistemica da virus dell'epatite C: la crioglobulinemia mista e altre manifestazioni extraepatiche. 2016 , 4, 1	
358	The Role of Direct Acting Anti-Virals in Chronic Hepatitis C Treatment-2016 Update. 2016 , 8,	

357	[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment]. 2016 , 67, 123-6	1
356	Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. 2016 , 22, 3460-70	8
355	Prioritizing Hepatitis C Treatment in U.S. Prisons. 2016 ,	
354	High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens. 2016 , 23, 667-76	5
353	Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan. 2016 , 46, 734-42	16
352	Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. 2016 , 63, 428-36	30
351	Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients. 2016 , 28, 997-1002	29
350	Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma. 2016 , 31, 1315-22	11
349	Why is viral eradication so important in patients with HCV-related cirrhosis?. 2017 , 22, 1-12	6
348	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. 2016 , 63, 418-27	29
347	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. 2016 , 19, 326-34	27
346	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016 , 10, 681-701	60
345	Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. 2016 , 19, 983-94	10
344	Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. 2016 , 61, 1214-25	98
343	Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy. 2016 , 6, 100-8	1
342	Men with severe hemophilia in the United States: birth cohort analysis of a large national database. 2016 , 127, 3073-81	74
341	Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. 2016 , 44, 866-76	7
340	Changing Cycle Lengths in State-Transition Models: Challenges and Solutions. 2016 , 36, 952-64	25

339	Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis. 2016 , 36,	99
338	Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate Cells. 2016 , 102, 121-49	13
337	Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute. 2016 , 3, 162-71	19
336	Surveillance for Hepatocellular Carcinoma. 2016 , 339-354	1
335	Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. 2016 , 139, 2519-28	27
334	Potential market size and impact of hepatitis C treatment in low- and middle-income countries. 2016 , 23, 522-34	14
333	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. 2016 , 1-22	
332	Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. 2016 , 65, S109-S119	43
331	Reversion of disease manifestations after HCV eradication. 2016 , 65, S95-S108	108
330	Management of the patient with SVR. 2016 , 65, S120-S129	37
329	Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. 2016 , 22, 1367-78	25
328	Hepatic Fibrosis in Hepatitis C. 2016 , 79-108	
327	Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. 2016 , 16, 91	7
326	Usefulness of MR elastography for detecting clinical progression of cirrhosis from child-pugh class A to B in patients with type C viral hepatitis. 2016 , 44, 715-22	19
325	Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. 2016 , 31, 1009-15	48
324	Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. 2016 , 10, 749-61	18
323	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. 2016 , 65, 727-733	612
322	Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. 2016 , 64, 1442-1450	107

321	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. 2016 , 31, 1168-76	33
320	Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. 2016 , 64, 790-9	53
319	Hepatitis E Virus Does Not Contribute to Hepatic Decompensation Among Patients With Advanced Chronic Hepatitis C. 2016 , 14, 896-902	5
318	Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. 2016 , 16, 285-94	13
317	Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. 2017 , 11, 38-44	13
316	Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus Infection. 2017 , 24, e670-e675	4
315	Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database. 2017 , 47, 283-292	7
314	Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. 2017 , 130, 746.e1-746.e7	51
313	Gut Microbiota and Complications of Liver Disease. 2017 , 46, 155-169	54
312	Sofosbuvir-velpatasvir for treating chronic hepatitis C. 2017 , 2, 156-157	1
311	Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era. 2017 , 24, 295-303	12
310	Hepatitis C Infection: A Systemic Disease. 2017 , 21, 449-453	21
309	Hepatitis C Virus Positive Patients on the Waiting List for Liver Transplantation: Turnover and Characteristics of the Population on the Eve of the Therapeutic Revolution With Direct-Acting Antivirals. 2017 , 49, 658-666	1
308	Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. 2017 , 47, 1429-1437	32
307	The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. 2017 , 46, 46-55	14
306	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. 2017 , 32, 1071-1078	5
305	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. 2017 , 11, 317-370	955
304	Hepatocellular Carcinoma After Sustained Virologic Response: Leave No One Behind. <i>Gastroenterology</i> , 2017 , 152, 1282-1284	133

303	Global epidemiology and burden of HCV infection and HCV-related disease. 2017 , 14, 122-132	233
302	Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation. 2017 , 24, 430-435	3
301	Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. 2017 , 37, 982-994	14
300	Cost-effectiveness of elbasvir/grazoprevir use in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. 2017 , 24, 268-279	12
299	The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. 2017 , 45, 455-467	15
298	Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers. <i>Gastroenterology</i> , 2017 , 153, 1531-1543.e2	13.3 31
297	Phytochemical Investigation, Antitumor Activity, and Hepatoprotective Effects of <i>Acrocarpus fraxinifolius</i> Leaf Extract. 2017 , 78, 210-226	5
296	Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. 2017 , 20, 1110-1120	11
295	Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data. 2017 , 149-178	
294	Clinical features of hepatitis B and C virus infections, with high α -fetoprotein levels but not hepatocellular carcinoma. 2017 , 96, e5844	6
293	Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. 2017 , 17, 1062-1068	238
292	Serum levels of anti-sperm-associated antigen 9 antibody are elevated in patients with hepatocellular carcinoma. 2017 , 14, 7608-7614	5
291	Ascites, refractory ascites and hyponatremia in cirrhosis. 2017 , 5, 104-112	31
290	Radiation Therapy for Liver Tumors. 2017 ,	
289	Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. 2017 , 65, 920-928	52
288	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. 2017 , 66, 485-493	160
287	Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoteric acid. 2017 , 42, 179-190	77
286	<i>Peromyscus</i> as a model system for human hepatitis C: An opportunity to advance our understanding of a complex host parasite system. 2017 , 61, 123-130	3

285	Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. 2017 , 11, 85-93	10
284	Hepatitis C. 2017 , 628-698	
283	Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030. 2017 , 17, 541	9
282	Association of TNF- α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. 2017 , 3, 16-22	1
281	The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC). 2017 , 18,	24
280	Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. 2017 , 9, 501-516	19
279	Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. 2017 , 12, e0169401	18
278	Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. 2017 , 12, e0176503	64
277	The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. 2017 , 12, e0182710	32
276	Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. 2017 , 23, 3163-3173	16
275	HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens. 2018 , 25, 969-975	10
274	Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. 2018 , 47, 1023-1031	18
273	The next wave of hepatitis C virus: The epidemic of intravenous drug use. 2018 , 38 Suppl 1, 34-39	20
272	Hypoalbuminemia is Associated With Significantly Higher Liver Transplant Waitlist Mortality and Lower Probability of Receiving Liver Transplant. 2018 , 52, 913-917	5
271	Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India. 2018 , 8, 241-249	4
270	Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. 2018 , 117, 1011-1018	7
269	The emergency medicine evaluation and management of the patient with cirrhosis. 2018 , 36, 689-698	11
268	Chronic Hepatitis C and Direct Acting Antivirals. 2018 , 11, 287-296	4

267	Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. 2018 , 19, 37-44	6
266	Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study. 2018 , 25, 47-55	6
265	Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. 2018 , 67, 482-491	18
264	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. 2018 , 67, 837-846	44
263	Performing Gadoteric Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. 2018 , 210, W63-W69	9
262	Clinical states of cirrhosis and competing risks. 2018 , 68, 563-576	158
261	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. 2018 , 53, 557-565	93
260	Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C. 2018 , 21, 19-26	9
259	Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. 2018 , 32, e13165	9
258	Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). 2018 , 38, 1022-1027	13
257	Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. 2018 , 53, 566-575	93
256	The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong. 2018 , 113, 2-4	9
255	Hepatitis C: una aproximaci3n cl3nica y epidemiol3gica en Cali, Colombia. 2018 , 33, 379	1
254	Transcatheter arterial chemoembolization monotherapy vs combined transcatheter arterial chemoembolization-percutaneous microwave coagulation therapy for massive hepatocellular carcinoma (≥10 cm). 2018 , 10, 5273-5282	4
253	Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients. 2018 , 2, 317-321	8
252	Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy. 2018 , 14, 783-791	2
251	Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China. 2018 , 38, 1031-1039	8
250	Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. 2018 , 32, 461-480	9

249	Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area. 2018 , 30, 1090-1096	4
248	Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail. 2018 , 13, e0201629	3
247	Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. 2018 , 18, 713-722	5
246	Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. 2018 , 33, 2029-2036	19
245	Primary Malignant Neoplasms of the Liver. 2018 , 705-729	1
244	Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance. 2018 , 19, 411-420	3
243	Optimal M-Switch Surveillance Policies for Liver Cancer in a Hepatitis C Infected Population. 2018 , 66, 673-696	5
242	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. 2019 , 39, 127-135	32
241	Hyponatremia Is Protective Against the Development of Portal Vein Thrombosis in Patients Undergoing Liver Transplant. 2019 , 51, 1880-1886	
240	Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy. 2019 , 49, 1441-1450	10
239	Hepatitis A, B, and C. 2019 , 697-710	
238	Direct acting antiviral-induced dynamic reduction of serum α -fetoprotein in hepatitis C patients without hepatocellular carcinoma. 2019 , 13, 658-666	1
237	Epidemiología, consumo de recursos y costos del manejo médico de la Hepatitis C en Argentina, Colombia, Uruguay y Venezuela. 2019 , 20, 180-190	1
236	Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. 2019 , 14, e0221614	4
235	Effect of exposure to Asian sand dust-Particulate matter on liver Tenascin-C expression in human cancer cell and mouse hepatic tissue. 2019 , 44, 633-641	1
234	Osteopathic Physical Exam Findings in Chronic Hepatitis C: A Case Study. 2019 , 11, e3939	7
233	Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data. 2019 , 26, 541-551	21
232	Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. 2019 , 69, 1888-1895	40

231	The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. 2019 , 50, 66-74	26
230	Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?. 2019 , 18, 144-156	6
229	Evaluation and Management of Cirrhotic Patients Undergoing Elective Surgery. 2019 , 21, 32	3
228	The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. 2019 , 54, 829-836	5
227	Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. 2019 , 9, e026726	26
226	Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. 2019 , 2, e193613	24
225	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. 2019 , 22, 693-703	8
224	Prioritizing Hepatitis C Treatment in U.S. Prisons. 2019 , 67, 853-873	7
223	Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. <i>Gastroenterology</i> , 2019 , 157, 54-64	13.3 156
222	Viral infection in primary antibody deficiency syndromes. 2019 , 29, e2049	14
221	Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis From Egypt. 2019 , 19, 51-58	1
220	Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. 2019 , 12, 502-508	0
219	Hepatitis C: Treatment. 2019 , 454-469	
218	Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study. 2019 , 9, 16849	10
217	The distribution of hepatitis C virus genotypes in patients with hepatocellular carcinoma. 2019 , 10, 28-32	
216	Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection. 2019 , 53, 262-268	2
215	The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study. 2019 , 69, 1442-1452	16
214	The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. 2019 , 91, 650-658	15

213	Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. 2019 , 118, 504-513	6
212	Clinical Epidemiology of Chronic Liver Diseases. 2019 ,	1
211	Clinical Epidemiology of Hepatitis C Virus. 2019 , 149-170	1
210	Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments. 2019 , 13, 699-708	3
209	The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis. 2019 , 9, 50-55	16
208	Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. 2019 , 9, 4-12	4
207	Natural History of Recurrent Alcohol-Related Cirrhosis After Liver Transplantation: Fast and Furious. 2020 , 26, 25-33	9
206	A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. 2020 , 37, 457-476	4
205	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. 2020 , 23, 180-190	0
204	Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. 2020 , 50, 426-438	8
203	Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs. 2020 , 128, 326-334	1
202	The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. 2020 , 20, 215	6
201	Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. 2020 , 10, e035224	5
200	Studies on the correlation between mutation and integration of HBV in hepatocellular carcinoma. 2020 , 40,	2
199	EASL Recognition Awardee 2020: Prof. Giovanna Fattovich. 2020 , 73, 484-486	
198	Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. 2020 , 18, 2554-2563.e3	21
197	Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan. 2020 , 10, 4089	6
196	Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China. 2020 , 17,	3

195	Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. 2020 , 17,	1
194	Viral Escape Mechanisms in Hepatitis C and the Clinical Consequences of Persistent Infection. 2020 , 868-888	
193	Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. 2021 , 66, 1315-1326	5
192	Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. 2021 , 25, 195-207	0
191	Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C. 2021 , 19, 371-387	1
190	The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. 2021 , 5, 83-96	4
189	Organ Donation and Transplantation in Sub-Saharan Africa: Opportunities and Challenges.	0
188	Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area. 2021 , 21, 34-44	
187	Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. 2021 , 51, 517-527	6
186	Iron at the Interface of Hepatocellular Carcinoma. 2021 , 22,	2
185	Grape seed extract ameliorated Ehrlich solid tumor-induced hepatic tissue and DNA damage with reduction of PCNA and P53 protein expression in mice. 2021 , 28, 44226-44238	5
184	From hepatitis A to E: A critical review of viral hepatitis. 2021 , 27, 1691-1715	13
183	Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. 2021 , 2021, 8811203	1
182	A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies. 2021 , 1-8	2
181	Evaluating the Effectiveness of the AIDS Education and Training Center (AETC) National Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Curriculum. 2021 , 8, 23821205211041178	
180	Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. 2020 , 3, e2021173	5
179	Viral Hepatitis and Hepatocellular Carcinoma. 2009 , 431-447	2
178	Natural history and disease manifestations of hepatitis C infection. 2000 , 242, 43-54	23

177	Natural History of Chronic Hepatitis C. 2016 , 3-55	1
176	Natural History, Pathogenesis, and Prevention of HCV Infection. 2012 , 11-19	1
175	Chronic Viral Hepatitis. 2010 , 1593-1617	1
174	Hepatitis C. 2010 , 2157-2185	4
173	Hepatitis C and Liver Transplantation. 2005 , 143-159	2
172	Hepatitis C. 2006 , 665-686	2
171	Liver Disease. 2012 , 1637-1693	4
170	Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. 2001 , 8, 1-18	55
169	Natural history of hepatitis C virus infection. 2000 , 15 Suppl, E105-10	29
168	Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. 2000 , 15 Suppl, E134-40	21
167	Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course?. 2000 , 15 Suppl, E141-51	18
166	Indications for liver transplantation for chronic viral hepatitis, and therapies for controlling hepatitis B virus infection before and after transplantation. 2000 , 15, E172-E174	3
165	Natural history of chronic hepatitis C. 2000 , 15 Suppl, E111-6	23
164	Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. 2000 , 46, 2050-68	245
163	Combination Interferon alfa-2b/ribavirin therapy for the treatment of hepatitis C: nursing implications. 2000 , 23, 55-62	6
162	Interferon therapy for chronic HCV hepatitis: trick or treat?. 1997 , 25, 310-3	1
161	Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection. 1999 , 28, 148-52	15
160	Antiviral therapy of HBV- and HCV-induced liver cirrhosis. 2000 , 30, 234-41	18

159	Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. 2000 , 19, 23-30	26
158	Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. 1998 , 66, 956-62	72
157	Impact of organ shortage on liver transplantation. 2001 , 6, 103-106	2
156	Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. 2018 , 30, 1277-1282	2
155	Hepatitis C Virus. 301-329	2
154	Influence of Genetic Polymorphisms of Tumor Necrosis Factor Alpha and Interleukin 10 Genes on the Risk of Liver Cirrhosis in HIV-HCV Coinfected Patients. 2013 , 8, e66619	14
153	Projections of the current and future disease burden of hepatitis C virus infection in Malaysia. 2015 , 10, e0128091	18
152	Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. 2015 , 10, e0133515	19
151	Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. 2015 , 10, e0141660	11
150	Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands. 2016 , 11, e0163488	28
149	Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography. 2017 , 12, e0170073	9
148	Risk Factors for the Development of Hepatocellular Carcinoma in Thailand. 2015 , 3, 182-8	17
147	Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. 2018 , 110, 621-628	7
146	Hepatocellular Carcinoma in Oman: An analysis of 284 cases. 2020 , 20, e316-e322	3
145	Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha. 2006 , 1, 399-409	2
144	The Natural History of Hepatitis C Viral Infection: Clinical Evaluation and Monitoring. 2016 , 3, 52-57	2
143	Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma. 2020 , 13, 68-74	4
142	The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation. 2014 , 18, i-xxii, 1-202	8

141	KASL clinical practice guidelines: management of hepatitis C. 2014 , 20, 89-136	30
140	KASL clinical practice guidelines: management of hepatitis C. 2016 , 22, 76-139	58
139	[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection]. 2008 , 14, 318-30	16
138	Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. 2013 , 1, 62-82	2
137	Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. 2006 , 12, 6771-8	5
136	Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. 2006 , 12, 7239-49	63
135	Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005). 2007 , 13, 1522-7	12
134	Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?. 2007 , 13, 4903-8	3
133	Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. 2007 , 13, 5648-53	67
132	Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. 2010 , 16, 3437-44	14
131	Clinical course of sub-centimeter-sized nodules detected during surveillance for hepatocellular carcinoma. 2012 , 18, 2654-60	5
130	Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients. 2014 , 20, 15387-97	3
129	Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. 2015 , 21, 4696-706	4
128	Impact of new treatment options for hepatitis C virus infection in liver transplantation. 2015 , 21, 10760-75	23
127	Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. 2016 , 22, 2630-5	5
126	Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. 2018 , 24, 315-322	11
125	Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. 2003 , 9, 1487-90	28
124	Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. 2017 , 22, 185-193	8

123	Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients. 2012 , 24, 323-31	23
122	Bone mineral density loss in patients with cirrhosis. 2018 , 24, 342-347	4
121	Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. 2013 , 5, 120-6	22
120	Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. 2014 , 6, 759-65	3
119	Clinical outcomes of compensated and decompensated cirrhosis: A long term study. 2014 , 6, 504-12	30
118	Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. 2015 , 7, 1312-24	16
117	Hepatitis C: Treatment of difficult to treat patients. 2015 , 7, 1953-63	17
116	Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. 2015 , 7, 2543-50	8
115	Diagnosis and treatment of hepatocellular carcinoma: An update. 2015 , 7, 362-76	88
114	Treatment strategies for chronic hepatitis C prior to and following liver transplantation. 2016 , 8, 69-73	10
113	Is the 25-year hepatitis C marathon coming to an end to declare victory?. 2017 , 9, 921-929	5
112	Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. 2012 , 6, 98-106	21
111	Chronic hepatitis C treatment: a review. 2000 , 20, 402-8	5
110	Serum viral markers in Iranian patients with congenital bleeding disorder. 2008 , 28, 453-5	3
109	Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. 2012 , 32, 174-99	19
108	New biomarkers for clinical management of hepatitis C virus infected patients. 2015 , 5, 59	1
107	Underutilization of palliative care services in the liver transplant population. 2016 , 6, 594-8	39
106	A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma. 2015 , 14, 869-80	12

105	Hepatitis C: an economic evaluation of extended treatment with interferon. 1999 , 171, 189-93	16
104	Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. 2004 , 1, 92-100	8
103	The natural history of hepatitis C virus (HCV) infection. 2006 , 3, 47-52	530
102	A practical approach to managing patients with HCV infection. 2006 , 3, 63-8	6
101	Clinicopathological characteristics of hepatocellular carcinoma in Turkey. 2012 , 13, 2985-90	13
100	Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. 1999 , 131, 696-701	61
99	Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China. 2021 , 12, 717504	
98	Liver disease severity predicts carcinogenesis of dysplastic liver nodules in cirrhosis. 2021 , 11, 20954	0
97	Hepatitis C Virus, Autoimmunity and Cancer. 2000 , 285-296	
96	Recent Advances in the Treatment of Hepatitis C. 2000 , 91-105	
95	Resolution of Fibrosis in Hepatitis C Patients with Sustained Response to Interferon: Long-Term Effects of Interferon Therapy on Histological Improvement. 2001 , 56-64	
94	Diagnosis and Management of Minor Medical Problems. 2001 , 143-154	
93	Hepatitis Viruses: The Natural History of Infection. 2002 , 1-22	
92	Resolution of hepatic fibrosis as a consequence of interferon therapy for hepatitis C. 2003 , 495-514	
91	Cancers of the large bowel and hepatobiliary tract. 2003 , 21, 509-34	
90	Indications and General Pathology of Liver Transplantation Candidates. 2003 , 71-82	
89	Resolution of Liver Fibrosis in Hepatitis C Patients by Interferon Therapy and Prevention of Hepatocellular Carcinoma. 2003 , 431-441	
88	Liver Transplantation. 2004 , 303-315	

- 87 Hepatozelluläres Karzinom. **2004**, 941-971
- 86 Favorable Outcome of Patients with C-Viral Liver Disease Treated with Interferon. **2004**, 167-175
- 85 Hepatitis C. **2004**, 117-143
- 84 Cancers of the large bowel and hepatobiliary tract. **2005**, 22, 443-69
- 83 Challenges and Controversies in the Management of Hepatitis C Virus Infection (Part 2). **2006**, 2006,
- 82 Immunopathogenesis and Outcomes of Recurrent Hepatitis C. **2007**, 459-470
- 81 Hepatitis C in Special Populations. **2009**, 97-134
- 80 Hepatocellular Cancer in Cirrhotic Patients: Radiological Imaging. **2009**, 261-273
- 79 Screening with Ultrasonography of Patients at High-Risk for Hepatocellular Carcinoma: Thrombocytopenia as a Valid Surrogate of Cirrhosis. **2009**, 137-144
- 78 9 Virale hepatitis. **2009**, 83-99
- 77 Hepatitis C. **2010**, 1313-1335.e6 1
- 76 Liver Transplantation. **2010**, 1593-1612.e2
- 75 Hepatitis C Virus.
- 74 Management of HCV Infection and Liver Transplantation. **2010**, 740-747
- 73 Disorders of the Liver, Biliary System and Exocrine Pancreas in Pregnancy. 223-255
- 72 Issues in Transplantation of Patients with Chronic Liver Failure. **2011**, 521-539
- 71 Simple and rapid detection of liver cirrhosis in children by tracking serum IgA/transferrin ratio. **2011**, 1, 117 1
- 70 Epidemiology of Chronic HCV. **2012**, 3-11

- 69 Chronic HCV and Hepatocellular Carcinoma. **2012**, 47-60
- 68 Hepatitis C. 582-652
- 67 Antivirals in Cirrhosis and Portal Hypertension. 132-139
- 66 Are Patterns and Prevalence Changing?. 1-10
- 65 Liver transplantation. **2012**, 1662-1673.e2
- 64 Emerging treatment advances in chronic hepatitis C. **2012**,
- 63 Elite portuguese soccer playersUse of psychological techniques: where, when and why. **2013**, 8, 847-860 1
- 62 The Immunopathogenesis of Cirrhosis. **2014**, 413-424 2
- 61 Hepatitis Viruses: Hepatitis C. **2014**, 765-783
- 60 Etiology. **2014**, 3-6
- 59 Intraoperative and Laparoscopic Ultrasound During Liver Surgery. **2014**, 201-218
- 58 Risk Factors for Hepatocellular Carcinoma Among Chronic Hepatitis C Patients Treated with Interferon. **1999**, 103-117
- 57 Hepatic Fibrosis and Cirrhosis. 2070-2086
- 56 Clinical Features. **2016**, 21-32
- 55 Model for End-Stage Liver Disease (MELD) Score as a Biomarker. **2016**, 1-24
- 54 Liver transplantation: Indications and general considerations. **2017**, 1737-1749.e2
- 53 Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. **2017**, 559-580
- 52 Model for End-Stage Liver Disease (MELD) Score as a Biomarker. **2017**, 47-70

51	AST-to-Platelet Ratio Index (APRI) as Marker in Liver Disease. 2017 , 305-320	
50	Is the 25-year hepatitis C marathon coming to an end to declare victory?.	
49	Pretransplant Evaluation and Care. 2018 , 737-752.e5	
48	Basic Techniques for Hepatic Resection by the Glissonean Approach. 2019 , 27-48	
47	Chronic hepatitis C: modern condition of the problem. 2019 , 23, 36-46	1
46	Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. 2019 , 13, 549-556	1
45	Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator. 2021 , 11, 21382	1
44	Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. 2021 , 99, 103458	1
43	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. 2020 , 26, S1-S40	4
42	Mortality Factors for Cirrhotics in an Ivorian University Hospital (Ivory Coast). 2020 , 10, 231-241	1
41	Liver. 2002 , 164-185	
40	Cancer of the Liver and Bile Ducts. 2006 , 752-770	
39	Treatment of Chronic Hepatitis C in Difficult-to-Treat Patients in the Clinical Setting. 2008 , 192-214	
38	Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. 2008 , 215-236	
37	Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. 1999 , 45 Suppl 6, VI1-VI22	12
36	Viruses and human cancer. 2006 , 79, 115-22	53
35	Hepatocellular carcinoma: an emerging problem with hepatitis C. 2000 , 92, 369-71	21
34	The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients. 2007 , 3, 4-32	2

33	Direct-acting antiviral agents in patients with hepatitis C cirrhosis. 2012 , 8, 727-65	3
32	Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. 2014 , 7, 21-27	5
31	The hepatitis C treatment revolution: how to avoid Asia missing out. 2015 , 1, 272-5	2
30	Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. 2016 , 6, Doc05	4
29	Medical Care of the Patient With Compensated Cirrhosis. 2006 , 2, 124-133	1
28	Understanding the natural history of chronic HBV and HCV infections. 2010 , 59, S17-22	1
27	Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis. 2018 , 10, 2685-2695	1
26	Hepatitis C and alcohol. 2003 , 27, 232-9	17
25	Value appropriation in hepatitis C. 2021 , 1	1
24	The Face of Hepatocellular Carcinoma (HCC) is Changing: Analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia.	0
23	Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma.. 2022 , 17, e0261619	0
22	The role of genetic mutation in alcoholic liver disease. 2022 , 12,	
21	EVOLUTION OF HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS CURED WITH DIRECT-ACTING ANTIVIRALS. LONG-TERM FOLLOW-UP.. 2022 ,	
20	Therapeutic Advances in Viral Hepatitis 'A-E.. 2022 , 39, 1524	
19	Cost-Effectiveness of a Core Antigen-Based Rapid Diagnostic Test for Hepatitis C.. 2022 ,	
18	Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis.. 2022 ,	0
17	Natural History Models for Hepatitis C-Related Liver Disease: Different Disease Progression Parameters for Different Settings. 2003 , 8, 365-372	17
16	Serum α Foetoprotein Level Predicts Treatment Outcome in Chronic Hepatitis C. 2007 , 12, 797-803	29

15	Natural History of Compensated and Decompensated HCV-Related Cirrhosis in HIV-Infected Patients: A Prospective Multicentre Study. 2007 , 12, 899-908	19
14	Pegylated Interferon- α 2b plus Ribavirin: An Efficacious and well-Tolerated Treatment Regimen for Patients with Hepatitis C virus Related Histologically Proven Cirrhosis. 2008 , 13, 663-673	30
13	Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients. 2022 , 58, 1015	1
12	ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: A multicenter case-control analysis. 12,	0
11	The Conundrum of Patients With Compensated Cirrhosis Requiring Kidney Transplantation; Kidney Alone or Simultaneous Liver Kidney Transplantation. Publish Ahead of Print,	0
10	Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease. 2022 , 5, e2230426	0
9	Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico. 2022 , 110, 103878	0
8	Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up. 2022 ,	0
7	Indication and Contraindications for Liver Transplantation. 2023 , 95-104	0
6	Hepatitis C: epidemiology, natural history, and diagnosis. 2023 , 229-250	0
5	Hepatitis C mortality trends in Mexico from 2001 to 2017. 2023 , 28, 101083	0
4	Natural History of Hepatosplenic Schistosomiasis (HSS) NonCirrhotic Portal Hypertension (NCPH): Influence of Gastrointestinal Bleeding and Decompensation in Prognosis. 2023 , 8, 145	0
3	Prediction of hepatic decompensation and hepatocellular carcinoma after direct-acting antiviral therapy in patients with hepatitis C-related liver cirrhosis: a cohort study. 2023 , 13,	0
2	PLATELET COUNT-SPLENIC DIAMETER RATIO AS A NON-INVASIVE PREDICTOR OF ESOPHAGEAL VARICES IN CIRRHOSIS. 2023 , 51-53	0
1	Diagnosis and management of hepatocellular carcinoma. 2007 , 13, 1	0